Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab + Pembrolizumab vs Pembrolizumab in 1L RM-HNSCC
NCT05980000Phase 2Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2023
- Primary completion
- Jun 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ramucirumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Washington University School of Medicine. Started Oct 2023; status: active, not recruiting.
02
Drugs
ramucirumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05980000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05980000.